351
Participants
Start Date
October 14, 2022
Primary Completion Date
February 26, 2027
Study Completion Date
February 26, 2027
Pembrolizumab
Pembrolizumab will be administered.
Dostarlimab
Dostarlimab will be administered
Belrestotug
Belrestotug will be administered.
Nelistotug
Nelistotug will be administered.
GSK Investigational Site, Ciudad Autonoma de Buenos Aire
GSK Investigational Site, Florida
GSK Investigational Site, Parktown
GSK Investigational Site, Wilrijk
GSK Investigational Site, Tatabánya
GSK Investigational Site, Santa Fe
GSK Investigational Site, Gyöngyös
GSK Investigational Site, Cape Town
GSK Investigational Site, Mar del Plata
GSK Investigational Site, Bangkok
GSK Investigational Site, Athens
GSK Investigational Site, Pathum Thani
GSK Investigational Site, Haidari - Athens
GSK Investigational Site, Marseille
GSK Investigational Site, Berlin
GSK Investigational Site, Caen
GSK Investigational Site, Genova
GSK Investigational Site, Turku
GSK Investigational Site, Incheon
GSK Investigational Site, Großhansdorf
GSK Investigational Site, Bergamo
GSK Investigational Site, Morgantown
GSK Investigational Site, Madrid
GSK Investigational Site, PamplonaNavarra
GSK Investigational Site, Madrid
GSK Investigational Site, Madrid
GSK Investigational Site, Pozuelo de AlarcOn Madr
GSK Investigational Site, Málaga
GSK Investigational Site, Quimper
GSK Investigational Site, Bordeaux
GSK Investigational Site, Plantation
GSK Investigational Site, Tampere
GSK Investigational Site, Istanbul
GSK Investigational Site, Las Palmas de Gran Canar
GSK Investigational Site, Verona
GSK Investigational Site, Chattanooga
GSK Investigational Site, Khon Kaen
GSK Investigational Site, Larissa
GSK Investigational Site, Guadalajara
GSK Investigational Site, Essen
GSK Investigational Site, Valencia
GSK Investigational Site, Valencia
GSK Investigational Site, Florence
GSK Investigational Site, Chiang Mai
GSK Investigational Site, Abu Dhabi
GSK Investigational Site, Thessaloniki
GSK Investigational Site, Samsun
GSK Investigational Site, Pylaia Thessaloniki
GSK Investigational Site, Thessaloniki
GSK Investigational Site, Pisa
GSK Investigational Site, Vaasa
GSK Investigational Site, Strasbourg
GSK Investigational Site, Heidelberg
GSK Investigational Site, San Luis Potosí City
GSK Investigational Site, Avellino
GSK Investigational Site, Albuquerque
GSK Investigational Site, Oulu
GSK Investigational Site, Kho Hong Hat Yai
GSK Investigational Site, Buenos Aires
GSK Investigational Site, Cipoletti Rio Negro
GSK Investigational Site, Ciudad Autonoma de Buenos Aire
GSK Investigational Site, San Juan
GSK Investigational Site, Barretos
GSK Investigational Site, Porto Alegre
GSK Investigational Site, São Paulo
GSK Investigational Site, Vitória
GSK Investigational Site, Jena
GSK Investigational Site, PapagosAthens
GSK Investigational Site, Budapest
GSK Investigational Site, Chiba
GSK Investigational Site, Fukuoka
GSK Investigational Site, Hyōgo
GSK Investigational Site, Kanagawa
GSK Investigational Site, Osaka
GSK Investigational Site, Saitama
GSK Investigational Site, Enschede
GSK Investigational Site, Groningen
GSK Investigational Site, Leeuwarden
GSK Investigational Site, Utrecht
GSK Investigational Site, Lublin
GSK Investigational Site, Prabuty
GSK Investigational Site, Siedlce
GSK Investigational Site, Gaia
GSK Investigational Site, Guimarães
GSK Investigational Site, Lisbon
GSK Investigational Site, Lisbon
GSK Investigational Site, Porto
GSK Investigational Site, Seoul
GSK Investigational Site, Seoul
GSK Investigational Site, Suwon Gyeonggi-do
GSK Investigational Site, Badajoz
GSK Investigational Site, Badalona
GSK Investigational Site, Barcelona
GSK Investigational Site, Barcelona
GSK Investigational Site, Ankara
GSK Investigational Site, Ankara
GSK Investigational Site, Antalya
GSK Investigational Site, Abu Dhabi
GSK Investigational Site, Middlesbrough
GSK Investigational Site, Middlesex
GSK Investigational Site, Wolverhampton
Lead Sponsor
Collaborators (1)
iTeos Therapeutics
INDUSTRY
GlaxoSmithKline
INDUSTRY